---
figid: PMC7601167__jcm-09-03214-g001
figlink: pmc/articles/PMC7601167/figure/jcm-09-03214-f001/
number: F1
caption: Graphical abstract depicting the mechanisms of inherent and acquired resistance
  to PI3K inhibition at different vertical nodes along the PI3K/Akt/mTOR pathway.
  Activating mutations and copy number amplifications in PIK3CA result in marked upregulation
  of PI3Kα signaling. Acquired resistance develops via activation of the CDK 4/6–cyclin
  D1 complex that may be blocked simultaneously to overcome this resistance. Alternatively,
  mTOR inhibition may synergize downstream with PI3Kα inhibition. Conversely, PIK3CA
  wild-type tumors are independent of PI3Kα activity, which makes them inherently
  resistant to PI3Kα inhibition. Hence, combining additional inhibition along the
  pathway may overcome this resistance and improve the efficacy of PI3K inhibitors.
pmcid: PMC7601167
papertitle: CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα
  Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
reftext: Eric Remer, et al. J Clin Med. 2020 Oct;9(10):3214.
pmc_ranked_result_index: '55158'
pathway_score: 0.9011788
filename: jcm-09-03214-g001.jpg
figtitle: Graphical abstract depicting the mechanisms of inherent and acquired resistance
  to PI3K inhibition at different vertical nodes along the PI3K/Akt/mTOR pathway
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7601167__jcm-09-03214-g001.html
  '@type': Dataset
  description: Graphical abstract depicting the mechanisms of inherent and acquired
    resistance to PI3K inhibition at different vertical nodes along the PI3K/Akt/mTOR
    pathway. Activating mutations and copy number amplifications in PIK3CA result
    in marked upregulation of PI3Kα signaling. Acquired resistance develops via activation
    of the CDK 4/6–cyclin D1 complex that may be blocked simultaneously to overcome
    this resistance. Alternatively, mTOR inhibition may synergize downstream with
    PI3Kα inhibition. Conversely, PIK3CA wild-type tumors are independent of PI3Kα
    activity, which makes them inherently resistant to PI3Kα inhibition. Hence, combining
    additional inhibition along the pathway may overcome this resistance and improve
    the efficacy of PI3K inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - MUT
  - AKT2
  - AKT3
  - AKT1
  - MTOR
  - CDK4
  - CDK6
  - E2F3
  - E2F8
  - E2F1
  - E2F2
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - GDCO032
  - Rb
genes:
- word: (PIK3CA
  symbol: PIK3CA
  source: hgnc_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: mut)
  symbol: MUT
  source: hgnc_symbol
  hgnc_symbol: MUT
  entrez: '4594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
chemicals:
- word: GDCO032
  source: MESH
  identifier: C073935
- word: Rb
  source: MESH
  identifier: D012413
diseases: []
figid_alias: PMC7601167__F1
redirect_from: /figures/PMC7601167__F1
figtype: Figure
---
